Abstract

Background: Uterine fibroids are the most common benign tumours in women of reproductive age group which may present with heavy menstrual bleeding, dysmenorrhea, pelvic pressure and anaemia. Its management depends on the number, size and location of the fibroids, patient’s age and desire to preserve fertility. Ulipristal acetate (UPA) is a selective progesterone receptor modulator which selectively inhibits the proliferation of uterine leiomyoma cells and induces their apoptosis. Objectives: The objective of the study was to evaluate the efficacy of ulipristal acetate in reducing the size of a symptomatic fibroid, its effect on menstrual bleeding, dysmenorrhea and its side effects. Materials and methods: A total of 45 patients were included in this prospective study. Oral ulipristal acetate at a dose of 5 mg per day was given for a period of 3 months. The PBAC Score, Visual Analogue Scale score and ultrasound findings of fibroid were noted. Results: Ulipristal acetate is an effective drug in reducing heavy menstrual bleeding, pain and fibroid size with minor side effects. Conclusion: Ulipristal acetate can be a safe, effective and economic option for treatment of symptomatic fibroids in patients.

References

1. Parker WH. Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril. 2007;87(4):725-36.
2. Kempson RL, Hendrickson MR. Smooth muscle, endometrial stromal, and mixed Müllerian tumors of the uterus. Mod Pathol. 2000;13(3):328-342.
3. Downes E, Sikirica V, Gilabert-Estelles J, Bolge SC, Dodd SL, Maroulis C, Subramanian D. The burden of uterine fibroids in five European countries. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2010 Sep 1;152(1):96-102.
4. Pritts EA, Parker WH, Olive DL. Fibroids and infertility: an updated systematic review of the evidence. Fertility and sterility. 2009 Apr 1;91(4):1215-23.
5. Englund K, Blanck A, Gustavsson I, Lundkvist U, Sjöblom P, Norgren A, Lindblom B. Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. The Journal of Clinical Endocrinology & Metabolism. 1998 Nov 1;83(11):4092-6.
6. Ichimura T, Kawamura N, Ito F, Shibata S, Minakuchi K, Tsujimura A, Umesaki N, Ogita S. Correlation between the growth of uterine leiomyomata and estrogen and progesterone receptor content in needle biopsy specimens. Fertility and sterility. 1998 Nov 1;70(5):967-71.
7. Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology & Metabolism. 2007 Sep 1;92(9):3582-9.
8. Woźniak S, Szkodziak P, Czuczwar P, Woźniakowska E, Paszkowski M, Milart P, Paszkowski T. The effect of ulipristal acetate treatment on symptomatic uterine fibroids within 12-months follow-up. Przeglad menopauzalny= Menopause review. 2014 Mar;13(1):18.
9. Nalini N, Bijeta, Singh JK. Ulipristal Acetate: A New Hope in the Conservative Management of Uterine Fibroid. International Journal of Contemporary Medical Research 2017; 4 (9).
10. Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, Ugocsai G, Mara M, Jilla MP, Bestel E, Terrill P. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine. 2012 Feb 2;366(5):409-20.
11. Donnez J, Vázquez F, Tomaszewski J, Nouri K, Bouchard P, Fauser BC, Barlow DH, Palacios S, Donnez O, Bestel E, Osterloh I. Long-term treatment of uterine fibroids with ulipristal acetate☆. Fertility and sterility. 2014 Jun 1;101(6):1565-73
12. Fernandez H, Schmidt T, Powell M, Costa AP, Arriagada P, Thaler C. Real world data of 1473 patients treated with ulipristal acetate for uterine fibroids: Premya study results. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2017 Jan 1;208:91-6
13. Singh K, Rai S. Efficacy of Ulipristal Acetate In Management of Symptomatic Uterine Fibroids: A Retrospective Study. International Journal of Scientific Research and Reviews. 2018;7(3):1192-1196.
14. Woodhead N, Pounds R, Irani S, Pradhan P. Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital. Journal of Obstetrics and Gynaecology. 2018 Mar 10:1-5.
15. Donnez J, Hudecek R, Donnez O, Matule D, Arhendt HJ, Zatik J, Kasilovskiene Z, Dumitrascu MC, Fernandez H, Barlow DH, Bouchard P. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertility and sterility. 2015 Feb 1;103(2):519-27.
16. Liu J, Soper D, Lukes AS, Gee P, Kimble T, Kroll R, Mallick M, Chan A, Sniukiene V, Shulman LP. VENUS II: the second us-based phase 3 study of ulipristal acetate (UPA) for treatment of symptomatic uterine fibroids (UF). Fertility and Sterility. 2017 Sep 30;108(3): e27-8.
17. Fauser BC, Donnez J, Bouchard P, Barlow DH, Vázquez F, Arriagada P, Skouby SO, Palacios S, Tomaszewski J, Lemieszczuk B, William AR. Safety after extended repeated use of ulipristal acetate for uterine fibroids. PloS one. 2017 Mar 7;12(3):e0173523.